Isabelle Peyrottes
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Isabelle Peyrottes has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Alexandre Bozec
Institut Universitaire de la Face et du Cou, Centre Antoine Lacassagne, 33 Avenue de Valombrose, 06189 Nice, France
1 shared publication - Clair Vandersteen
Université Côte d'Azur, laboratoire CoBTeK, Nice, France; Institut Universitaire de la Face et du Cou, UR2CA-REBOOT, 31 Avenue de Valombrose, 06100, Centre Hospitalier Universitaire, Université Côte d'Azur, Nice, Alpes-Maritimes, France
1 shared publication - Fanny Graslin
Laboratory Transporter in Imaging and Radiotherapy in Oncology (TIRO), UMR E4320 TIRO-MATOs, Direction de la Recherche Fondamentale (DRF), Institut des Sciences du Vivant Fréderic Joliot, Commissariat à l’Energie Atomique et aux Energies Alternatives (CEA), Faculté de Médecine, Côte d’Azur University, 28 Avenue de Valombrose, CEDEX 2, 06107 Nice, France
1 shared publication - Grégoire D'ANdrea
Otorhinolaryngology and Head and Neck Surgery Department, Institut Universitaire de la Face et du Cou, GHS Nice University Hospital - Antoine Lacassagne Centre, Université Côte d’Azur, Nice, France
1 shared publication - Isabel Gimenez
Department of Cytopathology and Anatomopathology, Antoine Lacassagne Center, 33 Av. de Valombrose, 06189 Nice, France
1 shared publication - Jean-Marie Guigonis
TIRO-MATOs - School of Medicine, University Cote d'Azur, FRANCE
1 shared publication
Latest Publications
- Open Access
- 23 June 2023
- Published by MDPI AG in Metabolites
- Vol. 13 (7) , 782
Pilot Study on the Use of Untargeted Metabolomic Fingerprinting of Liquid-Cytology Fluids as a Diagnostic Tool of Malignancy for Thyroid Nodules
Although it is the gold standard for assessing the malignancy of thyroid nodules (TNs) preoperatively, the cytological analysis of fine-needle aspiration cytology (FNAC) samples results in 20–30% of cases in indeterminate lesions (ITNs). As two-thirds of these lesions will appear benign after diagnostic surgery, improved preoperative diagnostic methods need to be developed. In this pilot study, we evaluate if the metabolomic profiles of liquid-based (CytoRich®) FNAC samples of benign and malignant nodules can allow the molecular diagnosis of TNs. We performed untargeted metabolomic analyses with CytoRich® FNAC in a monocentric retrospective study. The cohort was composed of cytologically benign TNs, histologically benign or papillary thyroid carcinomas (PTCs) cytologically ITNs, and suspicious/malignant TNs histologically confirmed as PTCs. The diagnostic performance of the identified metabolomic signature was assessed using several supervised classification methods. Seventy-eight patients were enrolled in the study. We identified 7690 peaks, of which 2697 ions were included for further analysis. We selected a metabolomic signature composed of the top 15 metabolites. Among all the supervised classification methods, the supervised autoencoder deep neural network exhibited the best performance, with an accuracy of 0.957 (0.842–1), an AUC of 0.945 (0.833–1), and an F1 score of 0.947 (0.842–1). Here, we report a promising new ancillary molecular technique to differentiate PTCs from benign TNs (including among ITNs) based on the metabolomic signature of FNAC sample fluids. Further studies with larger cohorts are now needed to identify a larger number of biomarkers and obtain more robust signatures.
- 23 June 2023
- Published by MDPI AG in Metabolites
- Vol. 13 (7) , 782
Open AccessPilot Study on the Use of Untargeted Metabolomic Fingerprinting of Liquid-Cytology Fluids as a Diagnostic Tool of Malignancy for Thyroid Nodules
Although it is the gold standard for assessing the malignancy of thyroid nodules (TNs) preoperatively, the cytological analysis of fine-needle aspiration cytology (FNAC) samples results in 20–30% of cases in indeterminate lesions (ITNs). As two-thirds of these lesions will appear benign after diagnostic surgery, improved preoperative diagnostic methods need to be developed. In this pilot study, we evaluate if the metabolomic profiles of liquid-based (CytoRich®) FNAC samples of benign and malignant nodules can allow the molecular diagnosis of TNs. We performed untargeted metabolomic analyses with CytoRich® FNAC in a monocentric retrospective study. The cohort was composed of cytologically benign TNs, histologically benign or papillary thyroid carcinomas (PTCs) cytologically ITNs, and suspicious/malignant TNs histologically confirmed as PTCs. The diagnostic performance of the identified metabolomic signature was assessed using several supervised classification methods. Seventy-eight patients were enrolled in the study. We identified 7690 peaks, of which 2697 ions were included for further analysis. We selected a metabolomic signature composed of the top 15 metabolites. Among all the supervised classification methods, the supervised autoencoder deep neural network exhibited the best performance, with an accuracy of 0.957 (0.842–1), an AUC of 0.945 (0.833–1), and an F1 score of 0.947 (0.842–1). Here, we report a promising new ancillary molecular technique to differentiate PTCs from benign TNs (including among ITNs) based on the metabolomic signature of FNAC sample fluids. Further studies with larger cohorts are now needed to identify a larger number of biomarkers and obtain more robust signatures.